Last updated September 10, 2026
Key finding
Omega-3 fatty acids decreased serum fasting blood glucose (FBG, p < 0.001)
This study investigated the effects of omega-3 fatty acids coadministered with glimepiride on glycemic control in patients with type 2 diabetes mellitus (T2DM). It found significant reductions in fasting plasma glucose and glycated hemoglobin levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of omega-3 fatty acids coadministered with glimepiride on glycemic control in patients with type 2 diabetes mellitus (T2DM). It found significant reductions in fasting plasma glucose and glycated hemoglobin levels.
These findings are clinically significant as they suggest that omega-3 fatty acids can enhance the effectiveness of glimepiride in managing blood sugar levels and improving lipid profiles in T2DM patients. This could lead to better overall management of diabetes and reduce the risk of cardiovascular complications associated with the disease.
Limited sample size may affect generalizability. Short duration of the study may not capture long-term effects. Potential for unmeasured confounders influencing results.
Published in
Publication details and source links for this paper.
Rehab HW, Aalaa R, Youssri NE, Maged WH. The effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control in T2DM patients. BMC Endocrine Disorders. 2023;23:259. doi:10.1186/s12902-023-01511-2
Omega-3 fatty acids decreased fasting plasma glucose by 3 mg/dl (p < 0.001)
Omega-3 fatty acids decreased glycated hemoglobin percent by 1.5% (p < 0.001)
Omega-3 fatty acids decreased total cholesterol by 7.4 mg/dl (p < 0.001)
Placebo did not significantly affect fasting plasma glucose levels.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to 1 g omega-3 fatty acids daily, Placebo with glimepiride and Atherogenic Index of Plasma Increase, Change in serum irisin level, Fasting Plasma Glucose (FPG), and 6 more.
This study contributes evidence to
Primary intervention
1 g omega-3 fatty acids daily
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
10
Evidence pairs
1344
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
1 g omega-3 fatty acids daily → Atherogenic Index of Plasma Increase
1 g omega-3 fatty acids daily → Atherogenic Index of Plasma Increase
1 g omega-3 fatty acids daily → Change in serum irisin level
1 g omega-3 fatty acids daily → Change in serum irisin level
1 g omega-3 fatty acids daily → Fasting Plasma Glucose (FPG)
1 g omega-3 fatty acids daily → Fasting Plasma Glucose (FPG)
1 g omega-3 fatty acids daily → High-density lipoprotein
1 g omega-3 fatty acids daily → High-density lipoprotein
1 g omega-3 fatty acids daily → Homeostatic model assessment for insulin resistance (HOMA-IR) change
1 g omega-3 fatty acids daily → Homeostatic model assessment for insulin resistance (HOMA-IR) change
1 g omega-3 fatty acids daily → Low-density lipoprotein
1 g omega-3 fatty acids daily → Low-density lipoprotein
1 g omega-3 fatty acids daily → Total cholesterol
1 g omega-3 fatty acids daily → Total cholesterol
1 g omega-3 fatty acids daily → Triglycerides
1 g omega-3 fatty acids daily → Triglycerides
Placebo with glimepiride → Fasting Plasma Glucose (FPG)
Placebo with glimepiride → Fasting Plasma Glucose (FPG)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on 1 g omega-3 fatty acids daily and Atherogenic Index of Plasma Increase, 1 g omega-3 fatty acids daily and Fasting Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies on 1 g omega-3 fatty acids daily
Contributes to 1 g omega-3 fatty acids daily evidence base.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies measuring Atherogenic Index of Plasma Increase
Measures Atherogenic Index of Plasma Increase as a key outcome.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
1 g omega-3 fatty acids daily appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
1 g omega-3 fatty acids daily appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
1 g omega-3 fatty acids daily appears to improve high-density lipoprotein.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
High-density lipoprotein
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
1 g omega-3 fatty acids daily appears to improve homeostatic model assessment for insulin resistance (HOMA-IR) change.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Homeostatic model assessment for insulin resistance (HOMA-IR) change
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
